Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 460 across all filing types
Latest filing 2022-08-04 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2022
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued shares, share options, warrants, and other share-related information for the month ended 31 July 2022. The content focuses on share capital changes, share options exercised, and confirmations related to securities issuance. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory submission reporting share capital movements and confirmations to the stock exchange, consistent with a Major Shareholding Notification or share capital movement report. Given the detailed share issuance and capital changes, the best fitting category is 'Share Issue/Capital Change' (SHA). The document length and detail confirm it is not a brief announcement but a substantive regulatory filing on share capital changes.
2022-08-04 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks for Ocumension Therapeutics, a listed issuer on the Stock Exchange of Hong Kong. It details the exercise of share options by directors and other participants, including the number of shares issued, issue prices, and confirmations by the board of directors regarding authorization and compliance with listing rules. The content focuses on share capital changes and disclosures required by listing rules, specifically referencing rule 13.25A of the Main Board Rules and GEM Rules. This type of document is a formal announcement of changes in share capital rather than a full financial report or earnings release. It fits the definition of a Share Issue/Capital Change announcement, which covers new share issues and capital changes. The document length (7900 characters) and detailed disclosure support this classification rather than a brief announcement or regulatory filing. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2022-07-18 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and/or share buybacks for Ocumension Therapeutics. It details the exercise of share options by a director, the number of shares issued, issue price, and closing balance of shares. The document references compliance with listing rules of the Stock Exchange of Hong Kong and includes confirmations by the board of directors regarding authorization and legal compliance. The content focuses on share capital changes and disclosures required by the exchange, not on financial results, management discussion, or other report types. It is a regulatory disclosure about share capital changes, fitting the category of Share Issue/Capital Change (SHA). The document length (7426 characters) and detailed data confirm it is the disclosure itself, not just an announcement of a report.
2022-07-15 English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2022
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return on movements in securities, specifically focusing on share capital, issued shares, share options, warrants, and other share-related movements for the month ended 30 June 2022. It is addressed to the Hong Kong Exchanges and Clearing Limited and includes confirmations by a company director regarding the authorization and compliance of the securities issued. The content is regulatory in nature, reporting share capital changes and share issuance details, but it is not a financial report, earnings release, or management discussion. It is also not an announcement of voting results, nor a proxy statement, nor a merger or acquisition document. The document is a regulatory filing reporting share capital movements and confirmations to the stock exchange, fitting the category of Regulatory Filings (RNS).
2022-07-05 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 24, 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the poll results from the Annual General Meeting (AGM) held on June 24, 2022. It details the voting outcomes on various resolutions including adoption of financial statements, re-election of directors, appointment of auditors, and share issuance mandates. The document does not contain the full financial report or detailed financial statements but rather the official voting results from the AGM. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document length is about 5970 characters, which is sufficient to include detailed voting results but not a full report. Therefore, the correct classification is DVA with high confidence.
2022-06-24 English
INSIDE INFORMATION NEW DRUG APPLICATION OF OUR CORE PRODUCT OT-401 APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is an announcement by Ocumension Therapeutics regarding the approval of a new drug application (NDA) for their core product OT-401 by the National Medical Products Administration (NMPA) in China. It is labeled as "INSIDE INFORMATION" and references compliance with the Listing Rules of the Hong Kong Stock Exchange. The content focuses on the drug approval news and its significance, with no financial statements, detailed financial data, or management discussion of financial results. The document length is 3936 characters, which is relatively short and typical for an announcement rather than a full report. There is no indication that this is a full annual or interim report, audit report, or earnings release. It is not a regulatory filing in the sense of officer certifications or compliance documents, but rather a material event announcement. Given the nature of the content and the regulatory context, this fits best as a Regulatory Filing (RNS) which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-06-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.